Dasapharm Limited Filleted Accounts Cover
Dasapharm Limited
Company No. 09325869
Information for Filing with The Registrar
31 December 2023
Dasapharm Limited Directors Report Registrar
The Directors present their report and the accounts for the year ended 31 December 2023.
Principal activities
The principal activity of the company during the year under review was wholesale pharmaceutical goods.
Directors
The Directors who served at any time during the year were as follows:
A. Katzman
D. Mevzos
The above report has been prepared in accordance with the provisions applicable to companies subject to the small companies regime as set out in Part 15 of the Companies Act 2006.
Signed on behalf of the board
D. Mevzos
Director
21 August 2024
Dasapharm Limited Balance Sheet Registrar
at
31 December 2023
Company No.
09325869
Notes
2023
2022
$
$
Fixed assets
Tangible assets
4
2,0326,823
2,0326,823
Current assets
Stocks
5
494,230128,950
Debtors
6
987,739772,089
Cash at bank and in hand
871,546667,777
2,353,5151,568,816
Creditors: Amount falling due within one year
7
(2,487,687)
(1,725,164)
Net current liabilities
(134,172)
(156,348)
Total assets less current liabilities
(132,140)
(149,525)
Net liabilities
(132,140)
(149,525)
Capital and reserves
Called up share capital
134134
Profit and loss account
8
(132,274)
(149,659)
Total equity
(132,140)
(149,525)
These accounts have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime of the Companies Act 2006.
For the year ended 31 December 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
As permitted by section 444 (5A)of the Companies Act 2006 the directors have not delivered to the Registrar a copy of the company's profit and loss account.
Approved by the board on 21 August 2024
And signed on its behalf by:
D. Mevzos
Director
21 August 2024
Dasapharm Limited Notes to the Accounts Registrar
for the year ended 31 December 2023
1
General information
Its registered number is: 09325869
Its registered office is:
C/O FKGB
2nd Floor
201 Haverstock Hill
London
NW3 4QG
The accounts have been prepared in accordance with FRS 102 Section 1A - The Financial Reporting Standard applicable in the UK and Republic of Ireland (March 2018) and the Companies Act 2006.
Going concern
These financial statements have been prepared on a going concern basis. The director, having considered the financial position of the company for a period of at least twelve months from the date of signing these financial statements, has no reason to believe that a material uncertainty exists that may cast doubt about the ability of the company to continue as a going concern. Accordingly the director has a reasonable expectation that the company will continue in operational existence and therefore he continues to adopt the going concern basis of accounting to prepare the financial statements.
2
Accounting policies
Turnover
Turnover is measured at the fair value of the consideration received or receivable. Turnover is reduced for estimated customer returns, rebates and other similar allowances.

Revenue from the sale of goods is recognised when all the following conditions are satisfied:
• the Company has transferred to the buyer the significant risks and rewards of ownership of the
goods;
• the Company retains neither continuing managerial involvement to the degree usually associated
with ownership nor effective control over the goods sold;
• the amount of revenue can be measured reliably;
• it is probable that the economic benefits associated with the transaction will flow to the Company;
and
• the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Specifically, revenue from the sale of goods is recognised when goods are delivered and legal title is passed.
Tangible fixed assets and depreciation
Tangible fixed assets held for the company's own use are stated at cost less accumulated depreciation and accumulated impairment losses.

At each balance sheet date, the company reviews the carrying amount of its tangible fixed assets to determine whether there is any indication that any items have suffered an impairment loss. If any such indication exists, the recoverable amount of an asset is estimated in order to determine the extent of the impairment loss.
Depreciation is provided at the following annual rates in order to write off the cost or valuation less the estimated residual value of each asset over its estimated useful life:
Furniture, fittings and equipment
25% straight line
Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the profit and loss account because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Judgements and key sources of estimation uncertainty
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors including expectations of future events that are believed to be reasonable under the circumstances.
Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Costs, which comprise direct production costs, are based on the method most appropriate to the type of inventory class, but usually on a first-in-first-out basis. Overheads are charged to profit or loss as incurred. Net realisable value is based on the estimated selling price less any estimated completion or selling costs.

When stocks are sold, the carrying amount of those stocks is recognised as an expense in the period in which the related revenue is recognised. The amount of any write-down of stocks to net realisable value and all losses of stocks are recognised as an expense in the period in which the write-down or loss occurs. The amount of any reversal of any write-down of stocks is recognised as a reduction in the amount of inventories recognised as an expense in the period in which the reversal occurs.

Work in progress is reflected in the accounts on a contract by contract basis by recording revenue and related costs as contract activity progresses.
Trade and other debtors
Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method, less impairment losses for bad and doubtful debts.
Trade and other creditors
Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.
Foreign currencies
The functional and presentational currency of the company is US Dollar. The accounts are rounded to the nearest dollar.
Transactions in currencies, other than the functional currency of the Company, are recorded at the rate of exchange on the date the transaction occurred. Monetary items denominated in other currencies are translated at the rate prevailing at the end of the reporting period. all differences are taken to the profit and loss account. Non-monetary items that are measured at historic cost in a foreign currency are not retranslated.
Provisions
Provisions are made where an event has taken place that gives the Company a legal or constructive obligation that probably requires settlement by a transfer of economic benefit, and a reliable estimate can be made of the amount of the obligation.

Provisions are charged as an expense to the profit and loss account in the year that the Company becomes aware of the obligation, and are measured at the best estimate at balance sheet date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties.

When payments are eventually made, they are charged to the provision carried in the balance sheet.
3
Employees
2023
2022
Number
Number
The average monthly number of employees (including directors) during the year was:
00
4
Tangible fixed assets
Fixtures, fittings and equipment
Total
$
$
Cost or revaluation
At 1 January 2023
18,71618,716
At 31 December 2023
18,71618,716
Depreciation
At 1 January 2023
11,89311,893
Charge for the year
4,7914,791
At 31 December 2023
16,68416,684
Net book values
At 31 December 2023
2,0322,032
At 31 December 2022
6,823
6,823
5
Stocks
2023
2022
$
$
Finished goods
494,230128,950
494,230128,950
6
Debtors
2023
2022
$
$
Trade debtors
979,770769,625
VAT recoverable
3,9541,939
Other debtors
3,476134
Prepayments and accrued income
539391
987,739772,089
7
Creditors:
amounts falling due within one year
2023
2022
$
$
Trade creditors
385,216459,888
Amounts owed to group undertakings
1,388,126
-
Other creditors
-1,232,681
Accruals and deferred income
714,34532,595
2,487,6871,725,164
8
Reserves
Profit and loss account - includes all current and prior period retained profits and losses.
9
Related party disclosures
Transactions with related parties
There was a balance of $1,388,126 (2022: $988,070) made up of loans and management fees owed to Dasapharm LTD (BVI) a company with a common Director.
Dasapharm Limited0932586931 December 202301 January 2023false21 August 2024BTCSoftware AP Solution 2024 11.1.0211.1.02true093258692023-01-012023-12-31093258692023-12-31093258692022-12-3109325869core:WithinOneYear2023-12-3109325869core:WithinOneYear2022-12-3109325869core:ShareCapital2023-12-3109325869core:ShareCapital2022-12-3109325869core:RetainedEarningsAccumulatedLosses2023-12-3109325869core:RetainedEarningsAccumulatedLosses2022-12-3109325869bus:RegisteredOffice2023-01-012023-12-3109325869core:FurnitureFittingsToolsEquipment2023-01-012023-12-31093258692022-01-012022-12-3109325869core:FurnitureFittingsToolsEquipment2023-01-01093258692023-01-0109325869core:FurnitureFittingsToolsEquipment2023-12-3109325869core:RetainedEarningsAccumulatedLosses2023-01-012023-12-3109325869bus:SmallEntities2023-01-012023-12-3109325869bus:FullAccounts2023-01-012023-12-3109325869bus:AuditExempt-NoAccountantsReport2023-01-012023-12-3109325869bus:Director22023-01-012023-12-3109325869bus:PrivateLimitedCompanyLtd2023-01-012023-12-31iso4217:USDxbrli:pure